Navigation Links
Heart Failure Patients With Normal Left Ventricular Ejection Fraction Don't Benefit From Treatment With Angiotensin II Receptor Blocker
Date:11/11/2008

Study highlights:

-- The angiotensin system inhibitor irbesartan did not improve outcomes in

heart failure patients with preserved left ventricular ejection

fraction.

-- There is not evidence-based therapy for this common condition that

predominantly affects women and older patients; more research into

mechanisms and potential therapies is critical.

NEW ORLEANS, Nov. 11 /PRNewswire-USNewswire/ -- An angiotensin II receptor blocker was no better than usual care for a type of heart failure that mostly affects women and the elderly, researchers reported at the American Heart Association's Scientific Sessions 2008. Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) was presented as a late-breaking clinical trial. The study was simultaneously published in the New England Journal of Medicine.

The major finding most people associate with a failing heart is a reduced ability to pump blood, called a low ejection fraction, said Barry M. Massie, M.D., co-principal investigator of the study, professor of medicine at the University of California, San Francisco and chief of the cardiology division at the San Francisco Veterans Administration Medical Center. But patients can also have heart failure with good heart pumping ability, a situation referred to as "preserved ejection fraction heart failure."

The world's largest placebo-controlled trial of an angiotensin II receptor blocker (ARB) in this syndrome included 4,128 participants (average age was 72, 60 percent were women) who were randomized to receive either irbesartan, an ARB currently used to treat blood pressure, or usual care for preserved ejection fraction heart failure. Researchers then followed them for 4.5 years to assess clinical outcomes.

"Typically, the public and physicians think of heart failure as a large, poorly contracting heart that can't pump adequate blood to the rest of the body with an ejection fraction of under 35 percent," Massie said. "But up to half of all heart failure patients have normal or preserved ejection fractions. Their hearts pump well and are not enlarged yet these patients still have the classic heart failure symptoms of fluid retention, shortness of breath and edema or swelling."

Compared to patients with low ejection fraction heart failure, those with preserved ejection fraction are older, more often women and are more likely to have high blood pressure. In this study, more than a third of participants were over age 75 and investigators reported high blood pressure as a heart failure cause in 64 percent of patients. The average of their ejection fraction was 59 percent.

Earlier studies suggested that patients with preserved ejection fraction heart failure may fare better on ARBs or ACE inhibitors than on conventional treatment but their results were not statistically significant, said Peter E. Carson, M.D., co-principal investigator, associate professor of medicine at Georgetown University and chief of the coronary care unit of Washington Veterans Administration Medical Center in Washington D.C.

In I-PRESERVE the primary outcome - a composite of all-cause death, hospitalization for heart failure, heart attack, unstable angina, arrhythmia and stroke - occurred in 742 people in the irbesartan group and 763 in the placebo group, a difference that was not statistically significant. Two major secondary endpoints, cardiovascular death and death or hospitalization specifically due to heart failure, were also not different between the treatment and control groups.

I-PRESERVE researchers found that the ARB was safe and well-tolerated, indicating that it could be a substitute for patients unable to tolerate other high blood pressure drugs.

Co-authors are: Michael Komajda, M.D.; Robert McKelvie, M.D.; John JV McMurray, M.D.; Michael Zile, M.D.; Mark Donovan, Ph.D.; Christoph Staiger, M.D.; and Agata Ptaszynska, M.D. Individual author disclosures are available on the abstract.

The study was funded by Bristol Myers Squibb and Sanofi-Aventis.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.americanheart.org/corporatefunding.


'/>"/>
SOURCE American Heart Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Drug for cluster headaches may cause heart problems
2. Use of certain lipid measures not more effective in predicting coronary heart disease
3. Restricting Blood Flow May Help Heart Bypass Patients
4. Urban Smog Tough on Young Adults Hearts
5. Stanford study highlights cost-effective method of lowering heart disease risks
6. Vitamin Es lack of heart benefit linked to dosage
7. Drug That Lowers Resting Heart Rate Being Tested
8. Heart Attack Boosts Diabetes Risk
9. Embryonic Stem Cells Repair Human Heart
10. U of M study: Early treatment can reverse heart damage
11. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Finn Mouseson”: ... take precedence in an average life. This mouse sets out on a journey that ... heart. “Finn Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, ...
(Date:9/20/2017)... ... ... “The Financial Favor of God; Second Edition”: a personal and exquisite recipe ... creation of published author, Brooks Rathell. , “We typically hear about the favor of ... financial favor of God. Not only does it exist, but it is meant for ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... MD (PRWEB) , ... September 19, 2017 , ... ... the Society of Professional Benefit Administrators (SPBA) hosted “Expanding Your Success” ... for SPBA Members as it focused on best practices for third party administrators ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
(Date:9/12/2017)...  ValGenesis Inc., the global leader in Enterprise ... announce the appointment of Dr. Ajaz Hussain ... Directors and Chairman of Advisory Board beginning September ... to manage their entire validation lifecycle process electronically ... process. Furthermore, ValGenesis VLMS enables rigorous compliance, helps ...
Breaking Medicine Technology: